GU Cancers 2022 | Neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccRCC

Mehmet Bilen, MD, Emory Winship Cancer Institute, Atlanta, GA, discusses the results of a Phase II study of neoadjuvant cabozantinib in patients with non-metastatic locally advanced non-metastatic clear cell renal cell carcinoma (ccRCC). Cabozantinib was clinically active and safe in the neoadjuvant setting in patients with locally advanced non-metastatic clear cell RCC. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.